Global Round Table: Experts Discuss BTK inhibitors for the Care of Patients With R/R MCL

Global Round Table: Experts Discuss BTK inhibitors for the Care of Patients With R/R MCL

Tuesday, January 17, 2023
Webinar -- 1:30 PM ET
https://www.clinicaloptions.com/MCLBTKiGlobalJoin1

Agenda

Welcome and Introductions 

Overview of Disease Burden in R/R MCL 

Role of Currently Available Irreversible Covalent BTK Inhibitors in MCL 

A New Era: Emerging Roles of Reversible Noncovalent BTKis in MCL 

Clinical Pearls and Insights: Regional Perspectives 

Case Discussions, Key Takeaways, and Audience Question and Answer Session

Faculty

Program Director
Julie M. Vose, MD, MBA

Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Faculty
Marco Ladetto, MD

Associate Professor
Dipartimento di Medicina Traslazionale
Università del Piemonte Orientale
Vercelli/Novara/Alessandria, Piedmont, Italy
Director of Hematology Oncology
SCDU Ematologia
AO SS Antonio E Biagio e Cesare Arrigo
Alessandria, Piedmont, Italy

Faculty
Max Topp, MD

Associate Professor
Head of the Hematology
Universitätsklinikum Würzburg
Med. Klinik und Poliklinik II
Zentrum Innere Medizin
Oberdürrbacher Str.6,
Würzburg, Germany

Program Overview
This program will provide expert perspectives on evidence-based clinical integration of new and emerging BTK inhibitors into the treatment algorithm and personalized care of patients with relapsed or refractory MCL, including discussions of the regional impact of the latest data, and strategies for the optimal selection and sequencing of BTK inhibitors, and management of the adverse events associated with these agents from a global point of view.

Goal Statement
The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatments for patients with relapsed/refractory MCL.

Target Audience
This globally focused educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat and manage patients with mantle cell lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate emerging BTK inhibitor data in the treatment of MCL considering the potential impact of safety and efficacy results on clinical practice
  • Plan BTKi-based therapeutic strategies for patients with R/R MCL, taking into consideration global indications and recent practice-changing clinical trial results
  • Select and sequence therapy for patients with MCL who have developed resistance to or intolerance of covalent BTKi-based therapy to optimize clinical outcomes
  • Identify patients with MCL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.